GU Cancers 2025 | Managing the common adverse events of avelumab in the clinic
Hiroshi Kitamura
• 13 Feb 2025
Hiroshi Kitamura, MD, PhD, University of Toyama, Toyama, Japan, comments on the management of immune-related adverse events (IRAEs) associated with avelumab. While the side effects such as interstitial lung disease (ILD), skin reactions, and colitis are mild, they require careful management. Physicians should collaborate with other specialists to address the aforementioned conditions. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
